Market Overview

Pluristem's PLX Cells Demonstrate Favorable Properties in Treatment of Tendon Injuries

Pluristem Therapeutics Inc. (NASDAQ: PSTI) announced today the results of a pre-clinical trial using the Company's PLacental eXpanded (PLX) cells in tendon injury. Dr. Scott Rodeo and his orthopedic research team at New York's Hospital for Special Surgery (HSS) studied the effects of PLX cells on rat patellar tendons that had sustained collagenase-induced injuries.

"Cell-based approaches clearly have great potential for the augmentation of connective tissue healing, as well as for tissue regeneration. As an 'off the shelf' cell source, PLX cells could provide an effective option to improve tendon healing," stated Scott Rodeo MD, Principal Investigator for this study and Professor of Orthopedic Surgery at Weill Cornell Medical College. Dr. Rodeo is Co-Chief of the Sports Medicine and Shoulder Service at Hospital for Special Surgery, New York; Associate Team Physician for the New York Giants Football Team; and Physician for the U.S.A. Olympic Swimming Team.

See full press release

Posted-In: News Guidance Contracts Management Global


Most Popular

Related Articles (PSTI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free